Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Eiger Biopharma (NQ: EIGR )

8.750 USD -0.290 (-3.21%)
Official Closing Price Updated: 7:52 PM EST, Nov 25, 2020 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Eiger Biopharma

< Previous 1 2 3 4 5 Next >
Eiger BioPharmaceuticals Announces FDA Approval of Zokinvy™ (lonafarnib): The First Treatment for Hutchinson-Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies
- Zokinvy increases survival by 2.5 years in children and young adults with Progeria 
From PR Newswire
Eiger BioPharmaceuticals Sells Priority Review Voucher for $95 Million
- Eiger and The Progeria Research Foundation will share proceeds 50/50 
From PR Newswire
Eiger BioPharmaceuticals Announces FDA Approval of Zokinvy™ (lonafarnib): The First Treatment for Hutchinson-Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies
- Zokinvy increases survival by 2.5 years in children and young adults with Progeria 
From PR Newswire
Eiger Announces Positive Peginterferon Lambda - Lonafarnib Combination End of Study Results from Phase 2 LIFT HDV Study in Late-Breaker Session at The Liver Meeting Digital Experience™ 2020
- Week 48 (24 Weeks Post-Treatment) Results Presented 
From PR Newswire
Eiger Announces Case Studies Demonstrating Regression of Liver Fibrosis Following 48 Weeks of Therapy with Peginterferon Lambda in Patients with Chronic Hepatitis Delta Virus (HDV) Infection Presented
Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of first-in-class therapies for serious rare and ultra-rare diseases, today announced a poster... 
From PR Newswire
Eiger Bio to Participate in November 2020 Investor Conferences
Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that management will... 
From PR Newswire
Eiger BioPharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Business Update
Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today reported financial results for third... 
From PR Newswire
Eiger Announces Abstracts Highlighting Peginterferon Lambda and Lonafarnib in Chronic Hepatitis Delta Virus (HDV) Infection Accepted for Presentation at The Liver Meeting Digital Experience™ 2020
Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted, first-in-class therapies for serious rare and ultra-rare diseases, today announced that data... 
From PR Newswire
Eiger BioPharmaceuticals Announces Positive Results of Investigator Sponsored Randomized Controlled Trial at University of Toronto with Peginterferon Lambda in Outpatients with Mild to Moderate COVID-
- Lambda significantly accelerated viral decline 
From PR Newswire
Eiger Announces Results of Investigator Sponsored Study in Outpatients with Mild and Uncomplicated COVID-19
Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced results of an investigator... 
From PR Newswire
Eiger Bio to Participate in September 2020 Investor Conferences
From PR Newswire
Eiger Announces Peginterferon Lambda - Lonafarnib Combination End of Treatment Results from Phase 2 LIFT HDV Study in Late Breaker Session at The Digital International Liver Congress™ 2020
- 96% of Patients Achieve Primary Endpoint of > 2 Log Decline in HDV RNA 
From PR Newswire
Eiger BioPharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Business Update
Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today reported financial results for... 
From PR Newswire
Eiger BioPharmaceuticals to Participate in Upcoming August 2020 Investor Conferences
Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that management will... 
From PR Newswire
Eiger BioPharmaceuticals, Inc. to Hold Virtual Annual Meeting of Stockholders on June 15, 2020
Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR) announced today that, due to public health and safety concerns related to the COVID-19 global pandemic, recommendations and orders from federal, state and... 
From PR Newswire
Eiger to Present at Jefferies Virtual Healthcare Conference 2020
Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that Eiger management will... 
From PR Newswire
Eiger BioPharmaceuticals Announces FDA Acceptance of NDA for Filing with Priority Review of Zokinvy™ (lonafarnib) for Treatment of Progeria and Progeroid Laminopathies
Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that the U.S. Food and... 
From PR Newswire
Eiger BioPharmaceuticals Reports First Quarter 2020 Financial Results and Provides Business Update
Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today reported financial results for... 
From PR Newswire
Eiger BioPharmaceuticals Announces First COVID-19 Patients Dosed with Peginterferon Lambda
- Six International, Investigator Sponsored Studies Initiating and Enrolling 
From PR Newswire
Eiger BioPharmaceuticals Announces EMA Validation of Lonafarnib MAA for Treatment of Progeria and Progeroid Laminopathies
- Accelerated Assessment of MAA Previously Granted by EMA in March 
From PR Newswire
Eiger BioPharmaceuticals Provides Update on Clinical Development Activities and Business Operations During COVID-19 Pandemic
- HDV Phase 3 D-LIVR Study Progressing; Impact to Timeline 
From PR Newswire
Eiger BioPharmaceuticals Completes Submission of New Drug Application to FDA for Lonafarnib for Treatment of Progeria and Progeroid Laminopathies
- Progeria MAA Submitted to EMA and Granted Accelerated Assessment 
From PR Newswire
Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
- Progeria MAA Submission Completed and Accelerated Assessment Granted by EMA 
From PR Newswire
Eiger BioPharmaceuticals Appoints Industry Veteran Eldon Mayer as Executive Vice President and Chief Commercial Officer
- Launch Preparation Underway for Lonafarnib in Progeria 
From PR Newswire
Eiger Updates on 2019 Progress and 2020 Milestones Expected
- Progeria Rolling NDA Planned for Completion in 1Q 2020 
From PR Newswire
Eiger Initiates Rolling Submission of New Drug Application (NDA) with FDA for Lonafarnib for Treatment of Progeria and Progeroid Laminopathies
- Rolling NDA Submission Planned for Completion in First Quarter 2020 
From PR Newswire
Eiger to Present at Jefferies 2019 London Healthcare Conference
Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that Eiger management... 
From PR Newswire
Eiger Announces Peginterferon Lambda - Lonafarnib Combination Interim Results in Hepatitis Delta Virus (HDV) Infection from Phase 2 LIFT Study During Late-Breaker Oral Presentation at AASLD 2019
- 53% of Patients Achieve Undetectable or BLOQ HDV RNA at Week 24 
From PR Newswire
Eiger BioPharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Business Update
- Successful Pre-NDA and Pre-MAA Meetings for Progeria & Progeroid Laminopathies 
From PR Newswire
Eiger Announces Peginterferon Lambda Combination Therapy for Treatment of Chronic Hepatitis Delta Virus (HDV) Infection to be Featured in a Late-Breaking Oral Presentation at AASLD 2019
- >50% of Patients Achieve Undetectable or BLOQ HDV RNA at Week 24 
From PR Newswire
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.